Table 1.
Investigational histone deacetylases inhibitors in pancreatic cancer patients
|
HDAC1 specificity
|
Intervention
|
Clinical trial phase
|
Study start date
|
Status
|
Clinical trial reference code
|
| Pan-HDAC | Vorinostat + Marizomib | I | March 2008 | Completed | NCT00667082 |
| Pan-HDAC | Vorinostat + Capecitabine + Radiation Therapy | I | October 2009 | Completed | NCT00983268 |
| Pan-HDAC | Vorinostat + Gemcitabine + Sorafenib + Radiation Therapy | I | January 2015 | Active | NCT02349867 |
| Pan-HDAC | Vorinostat + Radiation Therapy | I and II | March 2009 | Terminated | NCT00831493 |
| Pan-HDAC | Vorinostat + 5-fluorouracil + Radiation Therapy | I and II | August 2009 | Terminated | NCT00948688 |
| Pan-HDAC | Panobinostat + Bortezomib | II | September 2010 | Terminated | NCT01056601 |
| Class I | Entinostat | I | March 2001 | Completed | NCT00020579 |
| Class I | Entinostat + Nivolumab | II | November 2017 | Completed | NCT03250273 |
| Class I | Entinostat + ZEN003694 | I and II | March 2022 | Not yet recruiting | NCT05053971 |
| Class I | Entinostat + Molibresib | I | September 2020 | Withdrawn | NCT03925428 |
| Class I | Entinostat + FOLFOX2 | I | January 2021 | Withdrawn | NCT03760614 |
| Class I | Tacedinaline + Gemcitabine | II | October 1999 | Completed | NCT00004861 |
1
HDAC: Histone deacetylases.
2
FOLFOX regimen consists of folinic acid, 5-fluorouracil, and oxaliplatin.